Serum Levels of Resistin, Adiponectin, and Apelin in Gastroesophageal Cancer Patients

Table 1

Characteristics of study population.

2008–2012 years	Healthy controls; (𝑛=60)	Gastroesophageal cancer		𝑃-value
		Noncachexia; (𝑛=41)	Cachexia; (𝑛=44)
Age (years)	58.1 ± 4.2	61.8 ± 11.9	60.2 ± 9.0	0.780^a
Gender (male/female)	47/13	27/14	35/9	0.156^b
BMI (kg/m^2)	26.7 ± 2.7	24.9 ± 1.7	20.3 ± 2.2	<0.001^a
Localization
Esophagus	—	18 (43.9)	21 (47.7)	0.939^b
Cardia	—	11 (26.8)	11 (25.0)
Gaster	—	12 (29.3)	12 (27.3)
Operability (operable/not operable)	—	22/19	15/29	0.069^b
Histological type
Squamous cell carcinoma	—	18 (43.9)	21 (47.7)	0.724^b
Adenocarcinoma	—	23 (56.1)	23 (52.3)
TNM stage
II	—	10 (24.4)	0 (0.0)	0.002^b
III	—	12 (29.3)	15 (34.1)
IV	—	19 (46.3)	29 (65.9)

Data presented as mean ± SD or sizes (percent, %).
aOne-way ANOVA test, ^bchi-square, or Fisher exact tests.